Effects
of pyrethroid insecticide ICON (lambda cyhalothrin) on reproductive competence
of male rats
W.D. Ratnasooriya, S.S.K.
Ratnayake, Y.N.A. Jayatunga
Department of Zoology, University
of Colombo, Colombo-3, Sri Lanka
Asian
J Androl 2002
Mar;
4: 35-41
Keywords:
ICON; lambda cyhalothrin; pyrethroids; insecticides; sex behaviour; fertility;
sedation
Abstract
Aim: To assess the
effect of ICON (trade name of lambda-cyhalothrin) on sexual competence
and fertility of male rats. Methods: Male rats were gavaged daily
for 7 consecutive days with different doses of ICON (63 mg/kg and 100
mg/kg) or vehicle (distilled water). Their sexual behaviour and fertility
were evaluated at different time points during treatment and post-treatment
using receptive females. Results: Treatment had no effect on fertility,
but sexual competence was seriously impaired: libido (assessed in terms
of pre-coital sexual behaviour, and numbers of mounting, intromission
and ejaculation) sexual arousability/motivation (in terms of latencies
for mounting, intromission and ejaculation), sexual vigour (judged by
frequencies of mounting and intromission or copulatory efficiency). In
addition, ICON suppressed intromission ratio, indicating erectile dysfunction.
These effects on sexual function had a rapid onset and was reversible.
ICON-induced sexual dysfunction was mediated by multiple mechanisms, mainly
toxicity, stress, sedation and possibly via GABA and dopaminergic systems.
Conclusion: Exposure to ICON may cause sexual dysfunction in male
rats.
1
Introduction
Several currently used pesticides,
especially those having endocrine disruptive properties, are known to
adversely impair reproductive competence of males under laboratory, field,
clinical or occupational settings [1-5]. Some of these agents are among
the most commonly used pesticides/insecticides in developing countries
including Sri Lanka. Lambda-cyhalothrin (trade name: ICON) is a potent,
synthetic, type II pyrethroid [6,7] recently introduced to Sri Lanka as
an indoor spray against malaria vector mosquitoes (Manuweera G, Registrar
of pesticides, Sri Lanka, personal communication). It is also used as
an agropesticide in onion cultivation. It is a stomach, contact and a
residual insecticide, which acts as a neuropoison interfering in the ionic
conductance of nerve membranes by prolonging the sodium current [6,7].
In addition, pyrethroids increase the spontaneous release of neurotransmitters
such as GABA, dopamine or noradrenaline [7], and may also acts as hormone
disruptor [8]. Collectively, the facts suggest that ICON may disrupt male
reproductive function, but this has not been experimentally documented.
The aim of this study was to assess the potential
impacts of ICON on sexual competence and fertility of rats with a view
of possible extrapolation of the findings to man, as the processes and
regulation of male reproduction are highly conserved in mammals [9].
2
Materials
and methods
2.1 Animals
Sexually experienced
healthy adult crossbred albino rats (males weighing 225-250 g and females
200-225 g) were used. They were kept singly in plastic cages under standardized
animal house conditions (28-31℃, 12 h light/12
h darkness, relative humidity 50-55%) with free access to pelleted food
(Master Feeds Lanka Ltd., Colombo, Sri Lanka) and tap water.
2.2 ICON Preparation
Two desired doses (63
mg/kg and 100 mg/kg) of ICON was prepared by mixing the commercially available
ICON powder in distilled water (DW). The lower dose selected is close
to the reported oral no-observed-effect level of ICON, which was 50 mg/kg
[6].
2.3 ICON administration
ICON or vehicle was orally
administered by gastric intubation (09:00 - 10:00 h) for specified time
periods as indicated under relevant sub-sections. The first day of administration
was considered day 1 of treatment.
2.4 Adverse effects
After every dosing, cage
side observations were made on each rat continuously for 3 -5 h for mortality,
overt signs of toxicity (salivation, wilting, tremors, convulsions, ataxia,
yellowing of fur, diarrohea), stress (fur erection and exophthalmia) and
changes in non-sexual behaviours (such as cleaning of face, self grooming,
climbing in cages, rearings).
2.5 Fertility and general
toxicity evaluation
2.5.1 Animals and grouping
Male rats were assigned
to three groups: (1) ICON 63 mg/kg/day (n = 12), (2) ICON 100 mg/kg/day
(n = 17) and (3) 1 mL DW/day (n = 12) for 7 consecutive
days.
2.5.2 Effect on fertility
Rats were assessed for
their libido, ejaculatory ability and fertility on days 1, 3 and 7 of
treatment and then at weekly intervals for 90 days during the post-treatment
period. Each male was paired overnight with a pro-oestrous female (at
16.00-16.30 h). The pre-coital sexual behaviour (chasing, nosing, anogenital
sniffing, genital grooming, attempted clasping and mounting) of the paired
rats was observed for 2 h right after pairing. Vaginal smears of the females
were taken on the following morning (at 08:00 - 08:30 h). The presence
of spermatozoa was considered day 1 of pregnancy. If spermatozoa were
present, their numbers were determined in duplicate using an improved
Neubauer haemocytometer (Fision, UK) and gross morphology was observed
microscopically (100 and 400). If spermatozoa were absent,
then daily vaginal smearing was done for at least 10-12 days to determine
the appearance of pregnancy or pseudopreg-nancy. At 14 days following
pairing, the females were subjected to laparotomy under ether (Fluka,
Switzerland) anesthesia using aseptic precautions. The number of conceptus
(both viable and dead) was then determined. The following reproductive
indices were computed: index of libido= (number mated/number paired)100;
quantal pregnancy= (number pregnant/number mated )100; implantation index= (total
number of implantation/number mated)100; pre-implantation loss = [(number
of corpora lutea-number of implants)/number of corpora lutea]100; post-implantation loss = [(number
of implants - number of viable implants)/number of implants]100.
2.5.3 Effect on rectal temperature
The rectal temperature
was determined on days 1 and 7 of treatment (5 h after dosing) using a
clinical thermometer (Oson Duopris, Germany).
2.5.4 Effect on food and
water intake
Food and water intake
of the rats were determined daily on day 2-5 of treatment using standard
laboratory techniques [10].
2.5.5 Effect on body weight
Body weights were determined
5 h after dosing on days 1 and 7 of treatment using an electronic balance
(M.P. 6000, Chyo, Japan).
2.5.6 Effects on haematology
On day 1 post-treatment,
blood was collected from tails under aseptic conditions and red blood
cell (RBC) counts, white blood cell (WBC) counts, packed cell volume (PCV),
and haemoglobin content were estimated as described by Cheesbrough et
al [11]. Mean corpuscular haemoglobin concentration (MCHC) and mean
corpuscular volume (MCV) was then computed.
2.6 Evaluation of sedative
potential
The sedative potential
of ICON was evaluated using rat hole-board technique [12]. Forty-one male
rats were assigned into 3 groups and dosed similarly as in 2.5.1. Five
hours after the last dosing rats were individually placed on the center
of rat hole-board with a 7.5 min trial period. The number of headings,
rears and locomotory activity were recorded.
2.7 Evaluation of muscle
strength and co-ordination
Male rats were either
orally treated with 100 mg/kg/day of ICON (n = 6) or 1 mL DW/day
(n = 6) for 7 consecutive days. Five-seven h after the last dosing,
each of these rats were subjected to Bar Holding test to evaluate muscle
strength [13], and the time taken for the rat to fall from the bar was
determined. Immediately following this test, these rats were subjected
to Bridge test to evaluate the muscle co-ordination [13] and the latency
to slide off was recorded.
2.8 Effect on sexual behaviour
Forty one male
rats were divided and dosed similarly as in 2.5.1. On days 1, 3 and 7
of treatment (5-7 h following oral dosing) and day 14 post-treatment rats
were individually paired with a female rat brought into oestrous by subcutaneous
injection of 12 mg estradiol benzoate (Sigma, USA) and 48 h later by 0.5
mg of progesterone (Sigma, USA). The pre-coital and coital behaviour were
observed for 15 min or until ejaculation. During this period, the mount
latency, the intromission latency, the ejaculation latency, the number
of mounts and the number of intromissions were recorded. Using these parameters
the percentage of rats mounted, intromitted and ejaculated, and the intercopulatory
interval, the copulatory efficiency and the intromission ratio were calculated
[14].
2.9 Statistical analysis
The data are expressed as mean±SEM.
Statistical analyses were made using G- test (for quantal data),
and Mann-Whitney U-test and Student's t-test wherever appropriate.
Significance was set at P< 0.05.
3
Results
3.1 Adverse effects
Marked salivation [low
dose: 6 out of 12 (50%) and high dose: 7 out of 17 (41%)], ataxia [low
dose: 3 out of 12 (25%) and high dose: 5 out of 17 (29%)], mild diarrhoea
[low dose: 4 out of 12 (33%) and high dose: 5 out of 17 (29%)], mild fur
erection (in all treated rats), and exopthalmia [low dose: 1 out of 12
(8%) and high dose: 4 out of 17 (24%)] was evident. These effects appeared
2-3 h following each dose and persisted for 6-10 h. Nearly full recovery
was evident for all the manifestations. Furthermore, all non-sexual behaviours
observed were markedly impaired temporally. Treatment-related deaths:
2 with low dose and 5 with high dose.
3.2 Effects on fertility
Both low and high doses
markedly suppressed all pre-coital sexual behaviours monitored on days
1, 3 and 7 of treatment. Furthermore, as shown in
Figure 1, ICON caused a profound and significant (P< 0.05)
suppression in the index of libido on days 1 (both doses) and 7 ( high
dose) of treatment. On the other hand, ICON did not significantly impair
(P>0.05) other parameters of fertility during or after treatment.
Figure 1
3.3 Rectal temperature
ICON treatment did not
significantly (P> 0.05) alter rectal temperature (data not shown).
3.4 Food and water intake
ICON treatment caused
a significant (P<0.05) reduction in food intake (26-72%) on
day 2 [daily food intake in the control, low dose and high dose groups
being 22.2±1.0,
13.5±0.7
(by 39%), and 8.8±1.1
g (by 60%), respectively], and day 5 [23.2±0.8,
17.2±1.3
(by 26%), and 6.5±1.2
g (by 72%), respectively]. The effect appears to be dose-dependent. ICON
had no significant (P>0.05) effect on water intake (data not
shown).
3.5 Body weight
A significant (P<0.05)
suppression in body weight gain was evident in rats treated with ICON
(weight gain of the control, low dose and high dose groups being +4.1±2.9,
-6.6±4.2,
and -34.1±6.3
g, respectively).
3.6 Haematology
Both doses had no significant
effect on WBC and differential counts (data not shown). However, high
dose of ICON significantly lowered (P<0.05) the RBC count [the
control and high dose groups being 10.7±0.4
and 9.2±0.3106
cells/mm3 (by 14%), respectively], the PCV [45.0±1.0
and 37.6±1.4
% (by 16%), respectively], the MCHC [28.6±1.1
and 39.4±2.9
pg (by 38%), respec-tively] and the MCV [43.3±1.6
and 37.9±1.6
mm3 (by 12%), respectively].
3.7 Sedative effect
As shown in Table 1, low dose of ICON
significantly (P<0.05) impaired the locomotor activity (by 40%).
On the other hand, the high dose significantly (P< 0.05) inhibited
all the 3 parameters monitored: number of rears (by 63%), locomotor activity
(by 45%), and number of head dips (by 43%).
Table 1. Effect of ICON on sedative parameters
with rat hole-board technique. Range in parenthesis.
|
|
Locomotor
activity
|
Number
of rears
|
Number
of head dips
|
| Vehicle
(Distilled water)
|
19.9
±
2.7
(9 - 40)
|
17.8
±
4.0
(6 - 46)
|
8.3
±
1.1
(4 - 14)
|
| ICON
62.5 mg/kg
|
11.9
±
2.4b
(5 - 28)
|
14.8
±
2.4
(4 - 22)
|
5.9
±
0.8
(3 - 11)
|
| 100mg/kg
|
10.9
±
1.1b
(5 -16)
|
6.6
±
1.2b
(2-10)
|
4.7
±
0.7b
(2- 8)
|
As compared with control: bP
< 0.05, cP < 0.01 ( Mann-Whitney U-test,
Student t-test or G-test).
3.8 Muscle strength and co-ordination
ICON did not significantly
(P> 0.05) influenced the reaction time both in the Bar Holding
and the Bridge tests (data not shown).
3.9 Sexual behaviour
Table 2 summarizes the results obtained
with the sexual behaviour study. Most of the effects on the sexual behaviour
were evident on days 1 and 3 of treatment and some on day 7. The number
of rats attempting mounting (on day 1: low dose by 33%; high dose by 47%
and on day 3: low dose by 30%; high dose by 54%), intromission (on day
1: low dose by 33%; high dose by 47% and on day3: low dose by 30%; high
dose by 54%) and ejaculation (on day 1: low dose by 58%; high dose by
59%, on day 3: low dose by 30%; high dose by 54%) were significantly (P<0.05)
impaired. The time lags required for the initiation of each of these events
were also significantly (P<0.05) prolonged (on day 1, mounting:
low dose by 249% and high dose by 294 %, intromission: low dose by 231%
and high dose by 266%, and ejaculation: low dose by 43% and high dose
by 48%; on day 3, mounting: low dose by 540% and high dose by 905 %, intromission:
low dose by 540 % and high dose by 905%, and ejaculation: low dose by
63% and high dose by 75%; and on day 7, mounting: high dose by 238% and
ejaculation: low dose by 78%; high dose by 69%). However, the frequency
of mounting (by 57%) and intromission (by 56%) were inhibited significantly
(P<0.05) only with the high dose and only on day 1 of treatment.
Further, both the low and high doses of ICON significantly (P<0.05)
reduced the copulatory efficiency and intromission ratio. In contrast,
intercopulatory interval was not significantly (P>0.05) changed
by ICON treatments.
Table 2. Effect of
ICON on sexual behaviour of male rats.
Mean±SEM.
bP < 0.05, cP
< 0.01, compared with control. Range in parenthesis.
| |
|
Treatment |
Post-treatment |
| Day
1 |
Day
3 |
Day
7 |
Day
7 |
|
%
mounted |
Vehicle |
100 |
100
|
100
|
100 |
| 62.5
mg/kg |
67b |
70b
|
100 |
100 |
| 100
mg/kg |
53b
|
46c |
81 |
100 |
|
% intromitted |
Vehicle |
100 |
100 |
100 |
100 |
| 62.5
mg/kg |
67b
|
70b
|
80 |
100 |
| 100
mg/kg |
53b
|
46c
|
81 |
100 |
|
% ejaculated |
Vehicle |
100 |
100
|
100 |
100 |
| 62.5
mg/kg |
42c |
70b |
80 |
100 |
| 100
mg/kg |
41c
|
46c |
72b |
100 |
|
Number of mounts
|
Vehicle |
13.3
±
2.0
(5 - 24)
|
11.8
±
2.2
(8 - 21)
|
13.3
±
2.5
(5 - 23) |
13.8
±
1.5
(9 - 19) |
| 62.5mg/kg |
9.2
±
2.3
(0 - 23)
|
11.4
±
3.3
(0 - 32)
|
13.2
± 1.0
(10 - 15) |
11.7
± 3.6
(5 - 21) |
| 100
mg/kg |
5.7
±
1.6c
(0 - 18) |
6.1
±
2.8
(0 - 26)
|
7.6
± 1.9
(0 - 18) |
13.0
± 1.4
(8
- 18) |
|
Number of intromissions
|
Vehicle |
13.1±1.9
(5 - 24)
|
11.7
±
2.2
(8 - 21)
|
13.1
± 2.6
(5 - 23) |
13.7
± 1.6
(8 - 19) |
| 62.5
mg/kg |
9.0
±
2.2
(0 - 22)
|
11.4
± 3.3
(0 - 32) |
11.2
± 2.4
(0 - 15) |
11.5
± 3.6
(5
- 21) |
| 100
mg/kg |
5.7
±
1.6c
(0 - 18) |
6.1
± 2.8
(0
- 26) |
7.2
± 1.8
(0 - 17) |
12.9
± 1.5
(8
- 18) |
|
Mount latency |
Vehicle |
131.0
±
32
(60 - 300)
|
60.0
± 5.0
(60 - 90) |
102.9
± 29.2
(60
- 270) |
95.0
± 19.6
(60 - 180) |
| 62.5
mg/kg |
457.5
±
99.7c
(90 - 900) |
384.0
± 114.0b
(60
- 900) |
288.0 ± 131.0
(60 - 900) |
67.5
± 7.5
(60
- 90) |
| 100
mg/kg |
517.1±
91.0c
(90 - 900) |
603.0
± 111.0c
(60 - 570) |
348.0
± 125b
(60 - 900) |
77.1
± 8.9
(60 - 120) |
|
Intromission Latency
|
Vehicle |
141.1
±
30.6
(60 - 300)
|
60.0
±
5.0
(60 - 90) |
107.1
± 29.9
(60 - 270) |
100.0
± 18.4
(60 - 180) |
| 62.5
mg/kg |
467.5
±
97.7c
(90 - 900) |
384.0
± 114.0b
(60
- 900) |
310.0±
135.0
(60 - 900) |
75.0
± 8.7
(60 - 180) |
| 100
mg/kg |
517.1c
±
91.0
(90 - 900)
|
603.0
± 111.0c
(60
- 570) |
85.7
± 102
(60 - 900) |
366.1
± 119b
(60 - 120) |
|
Ejaculation latency
|
Vehicle |
516.7
±
74.5
(150 - 810)
|
455.0
± 78
(150
- 660) |
390.0
± 59.6
(150 - 660) |
560.0
± 97.6
(240
- 840) |
| 62.5
mg/kg |
737.5
±
66.5b
(390 - 900)
|
741.0
± 55.3c
(510 -
900) |
695.0
± 110b
(210 - 900) |
465.0
± 154
(150 - 870) |
| 100
mg/kg |
764.1
± | |